Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.56 |
| ▸ | HTR2C | P28335 | 5/20 | 0.56 |
| ▸ | HTR2B | P41595 | 5/20 | 0.56 |
| ▸ | KDM1A | O60341 | 3/20 | 0.44 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13272292 | 1.00 | HTR2A (0.56) | HTR2AHTR2CHTR2BKDM1ARCOR1 | |
| SCHEMBL19444237 | 1.00 | HTR2A (0.56) | HTR2AHTR2CHTR2BKDM1ARCOR1 | |
| SCHEMBL17147624 | 0.82 | HTR2A (0.46) | HTR2AHTR2CHTR2BKDM1ARCOR1 | |
| SCHEMBL19102679 | 0.82 | HTR2A (0.46) | HTR2AHTR2CHTR2BKDM1ARCOR1 | |
| SCHEMBL3422301 | 0.79 | HTR2C (0.61) | HTR2AHTR2CHTR2BKDM1ARCOR1 | |
| SCHEMBL3419759 | 0.79 | HTR2C (0.61) | HTR2AHTR2CHTR2BKDM1ARCOR1 | |
| SCHEMBL6998583 | 0.79 | HTR2C (0.61) | HTR2AHTR2CHTR2BKDM1ARCOR1 | |
| SCHEMBL3031647 | 0.79 | HTR2C (0.61) | HTR2AHTR2CHTR2BKDM1ARCOR1 | |
| SCHEMBL23993595 | 0.77 | HTR2A (0.50) | HTR2AHTR2CHTR2BKDM1ARCOR1 | |
| SCHEMBL13251359 | 0.77 | HTR2A (0.50) | HTR2AHTR2CHTR2BKDM1ARCOR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023011488-A1 | PHARMACEUTICAL COMBINATION AND USE THEREOF | 苏州亚盛药业有限公司 | 2023-02-09 | — | — | WO | disclosed |
| US-20210290594-A1 | BISDIAZABICYCLO COMPOUND FOR TREATMENT AND/OR PREVENTION OF HEPATITIS VIRUS-RELATED DISEASES OR DISORDERS | HealthQuest Pharma Inc. (CN) | 2021-09-23 | — | — | US | disclosed |
| WO-2021110011-A1 | COMBINATION OF IAP INHIBITORS AND PARP OR MEK INHIBITORS OR OTHER CHEMOTHERAPEUTIC AGENTS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2021-06-10 | — | — | WO | disclosed |
| WO-2020024932-A1 | METHOD FOR TREATING CANCER BY COMBINATION OF IAP INHIBITOR AND MODULATOR OF IMMUNE CHECKPOINT MOLECULE | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-02-06 | — | — | WO | disclosed |
| EP-2888265-B1 | BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC METHODS USING THE SAME | UNIV MICHIGAN REGENTS (US) | 2017-10-11 | — | — | EP | disclosed |
| US-8883771-B2 | Bivalent inhibitors of IAP proteins and therapeutic methods using the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-11-11 | — | — | US | disclosed |
| US-20140057924-A1 | BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC METHODS USING THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2014-02-27 | — | — | US | disclosed |
| US-8299100-B2 | Potent and selective neuronal nitric oxide synthase inhibitors with improved membrane permeability | NORTHWESTERN UNIVERSITY (US) | 2012-10-30 | — | — | US | disclosed |
| WO-2011021645-A1 | BICYCLIC UREA DERIVATIVE OR PHARMACOLOGICALLY PERMITTED SALT THEREOF | 大日本住友製薬株式会社 (JP) | 2011-02-24 | — | — | WO | disclosed |
| WO-2010085749-A2 | POTENT AND SELECTIVE NEURONAL NITRIC OXIDE SYNTHASE INHIBITORS WITH IMPROVED MEMBRANE PERMEABILITY | NORTHWESTERN UNIVERSITY (US) | 2010-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210290594-A1 | BISDIAZABICYCLO COMPOUND FOR TREATMENT AND/OR PREVENTION OF HEPATITIS VIRUS-RELATED DISEASES OR DISORDERS | HAVCR2, NR1H4, SLC10A1 | HTR2A 3770/4885HTR2C 3817/4885HTR2B 3684/4885 |
| US-20140057924-A1 | BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC METHODS USING THE SAME | BIRC2, BIRC5, BIRC7 | HTR2A 4412/4885HTR2C 4704/4885HTR2B 4357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.